15.81
price up icon1.61%   0.25
after-market Handel nachbörslich: 15.90 0.09 +0.57%
loading
Schlusskurs vom Vortag:
$15.56
Offen:
$15.56
24-Stunden-Volumen:
738.01K
Relative Volume:
0.69
Marktkapitalisierung:
$789.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-4.2846
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+4.22%
1M Leistung:
+30.12%
6M Leistung:
+84.70%
1J Leistung:
+4.43%
1-Tages-Spanne:
Value
$15.21
$15.91
1-Wochen-Bereich:
Value
$15.09
$16.23
52-Wochen-Spanne:
Value
$7.30
$16.32

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Firmenname
Kalvista Pharmaceuticals Inc
Name
Telefon
(857) 999-0075
Name
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Mitarbeiter
270
Name
Twitter
@kalvista
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
KALV's Discussions on Twitter

Vergleichen Sie KALV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
15.81 757.80M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Eingeleitet JMP Securities Mkt Outperform
2025-01-07 Eingeleitet TD Cowen Buy
2024-12-18 Eingeleitet BofA Securities Buy
2020-06-15 Eingeleitet H.C. Wainwright Buy
2019-07-29 Eingeleitet SVB Leerink Outperform
2019-03-20 Eingeleitet Needham Buy
2018-10-30 Eingeleitet Jefferies Buy
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2017-08-31 Eingeleitet BTIG Research Buy
Alle ansehen

Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives KalVista Pharmaceuticals Inc. stock priceOutstanding yields - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about KalVista Pharmaceuticals Inc. stockSuperior trading gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 20, 2025

KalVista Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional

Jul 20, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista's Ekterly OK'd as on-demand HAE swelling attack treatment in UK - Angioedema News

Jul 17, 2025
pulisher
Jul 16, 2025

(KALV) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Jul 16, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

MHRA approves Ekterly to treat HAE - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Jul 14, 2025
pulisher
Jul 13, 2025

Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 11, 2025

Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista price target raised to $27 from $19 at Citizens JMP - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Shares Fall After Fiscal 2025 Results - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30Earnings Summary - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharmaceuticals IncFDA approves Kalvista's Ekterly for hereditary angioedema - MarketScreener

Jul 10, 2025
pulisher
Jul 09, 2025

KalVista price target raised to $37 from $22 at BofA - Yahoo Finance

Jul 09, 2025

Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):